ANTCHAIN
23.6.2021 10:52:08 CEST | Business Wire | Press release
AntChain, Ant Group’s technology brand, today launched a developer community support program at its first developer conference. The program is designed to further foster trusted industry collaboration networks with blockchain, secure computing, IoT, and other innovative technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005429/en/
This new program will bring AntChain's technical know-how and industry experience to partners and developers across a variety of platforms. Among them, the AntChain open technology platform will serve to accelerate the development of blockchain applications as well as reduce costs, while the AntChain open business ecosystem will help connect partners and developers with complementary business opportunities and operational resources. A new talent certification system has also been put in place to support technical professionals’ career development through training and certification standards.
So far, the AntChain developer community has included over 330 institutional partners and nearly 10,000 developers, who together have created over 30 innovative industry applications, including an eSign electronic contracting service and a blockchain-powered rural property trading platform with NDSCSoft.
“With the further digitalization of our economy and society, we have seen trends shifting from the digitalization of single organizations to the digitalization of industry partnerships and collaborations,” said Geoff Jiang, President of Ant Group’s Intelligent Technology Business Group. “We are committed to working more closely with our partners and developers to explore new synergies, resolve pain points in industry collaborations, and uncover greater value for the global economy and our societies."
During the conference, developers from across various industries also shared their experience and best practices on integrating AntChain's technology into their day-to-day operations. “AntChain's technology can help strengthen the efficiency of multi-party collaborations, while enhancing trust in traditional rural property transactions, in turn acting as a frictionless and more efficient solution for customers in rural areas,” said Wang Liping, Deputy General Manager of NDSCSoft.
At today's conference, AntChain also announced the launch of a suite of new innovative technologies and products, including the Blockchain Transmission Network (BTN), a high-speed, long-distance blockchain communication technology, and the AntChain Module-as-a-Service (MaaS) integrated computing module for simplified blockchain deployment.
BTN improves the data throughput and stability of blockchains through high-speed communications technology. It can enhance the throughput of a blockchain network by 186%, reduce its bandwidth cost by 80%, and cut transmission latency by 40%.
AntChain MaaS lowers the technical and financial costs of deploying blockchain hardware, and ensures the security and immutability of data transmission with technologies including silicon root of trust, digital signature at source and end-to-cloud integration.
AntChain’s technologies and solutions have been deployed in more than 50 use cases typically involving multi-party collaborations, including supply chain finance, IT leasing, global shipping, cross-border remittance, and more. On June 10, AntChain also announced a five-year global partnership with UEFA to jointly explore how blockchain technology can be used to accelerate the digital transformation of the football industry.
About AntChain
AntChain is Ant Group’s technology brand. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations, and product provenance.
The AntChain platform consists of three layers including the underlying Blockchain-as-a-Service open platform, the digitalization of assets, and the circulation of digitalized assets. By enabling businesses to digitalize their assets and transactions, AntChain establishes trust in multi-party collaborations. The AntChain platform generated over 100 million daily active items such as patents, vouchers, and warehouse receipts, for the twelve months ended June 30, 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005429/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom